Bayesian Secondary Reanalysis of Published Aggregate Data on Circulating Tumor DNA for Molecular Residual Disease Detection Across Cancer Types.
Tracking circulating tumor DNA after cancer treatment may help predict who will relapse, guiding when to intensify surveillance.
Background Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing may help estimate recurrence risk after treatment. Longitudinal monitoring may improve sensitivity, while assay technology comparisons should be interpreted cautiously because they were based on aggregate, non-head-to-head data.
What the study was
- Study design
- Observational/unspecified
- Population
- cancer patients
- Sample size
- 9980
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Annals of clinical biochemistry
Why it surfaced
Score 6/10 [EARLY_CANCER_DETECTION]: Observational/unspecified (Journal Article) matched 'Early cancer detection (liquid biopsy, c'. Components — novelty:1/3, relevance:2/3, design:1/2, population:2/2. Confidence: medium. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.